Berk R N, Loeb P M
Semin Roentgenol. 1976 Jul;11(3):147-56. doi: 10.1016/0037-198x(76)90043-2.
(1) Solubilization of Telepaque in the intestine is a limiting factor in the rate of intestinal absorption. Bilopaque and Oragrafin are more water-soluble and appear to be better absorbed than Telepaque. (2) Bile salts in the intestinal lumen increase the solubility of Telepaque. Therefore, a fatty meal administered with the Telepaque is desirable to evacuate bile salts from the gallbladder into the intestine. This is not required for the more water-soluble agents, Biopaque and Oragrafin. (3) The degree of protein binding of the contrast agents can be related to the degree of toxicity. Cholografin is the most highly bound and is the most toxic. (4) Hepatic receptor proteins may specifically bind the biliary contrast agents. This may be the reason that the renal contrast materials are poorly escreted in bile compared to the biliary contrast agents. (5) Telepaque is conjugated in the liver with glucuronide making the compound more soluble in bile. This prevents precipitation of Telepaque in the gallbladder and avoids reabsorpiton from the intestine. (6) The biliary excretion of Telepaque is facilitated by bile salts. Therefore, the administration of a fatty meal with Telepaque not only increases the rate of intestinal absorption of Telepaque but also the rate of biliary excretion. (7) The rate of biliary excretion of both the oral and the intravenous contrast agents appears to be limited by a hepatic transport maximum. Above a certain dose, increased amounts of the contrast agents do not result in more rapid excretion of the agents into bile. Rapid infusion of intravenous contrast agents results in high plasma concentration and greater urinary excretion, without increasing the biliary excretion. It does not appear to be indicated in clinical practice. (8) The biliary concentration of the contrast agents used for intravenous cholangiography is determined by their rate of biliary excretion, the choleretic effect of the contrast agent, and factors that determine the rate of basal bile flow. Fixed coupling of water with the biliary excretion of these contrast agents imposes an inherent limitation on the concentration of the contrast agent in bile. It appears that the biliary concentration of the intravenous contrast materials can be increased by having the patient fast prior to intravenous cholangiography. This decreases the enterohepatic circulation of bile salts and the rate of bile-salt-dependent bile flow. (9) Failure of the gallbladder to visualize after administration of Telepaque when there is adequate biliary excretion may be due to cystic duct obstruction, failure of the inflamed gallbladder mucosa to reabosrb water, or reabsorption or the contrast agent by the diseased gallbladder mucosa. (10) Maximum concentration of Telepaque occurs at 14-19 hr after ingestion. It is at this time that radiographs of the gallbladder should be made. With Bilopaque, peak concentration occurs at 10 hr so radiographs can be made earlier when Bilopaque is used.
(1) 碘番酸在肠道中的溶解是肠道吸收速率的一个限制因素。胆影葡胺和碘奥酮的水溶性更高,似乎比碘番酸吸收得更好。(2) 肠腔内的胆盐会增加碘番酸的溶解度。因此,与碘番酸一起服用一顿高脂餐有助于将胆盐从胆囊排空到肠道。对于水溶性更高的制剂胆影葡胺和碘奥酮则不需要这样做。(3) 造影剂的蛋白结合程度可能与毒性程度相关。胆影钠的蛋白结合程度最高,毒性也最大。(4) 肝脏受体蛋白可能会特异性结合胆道造影剂。这可能就是与胆道造影剂相比,肾造影剂在胆汁中排泄较差的原因。(5) 碘番酸在肝脏中与葡糖醛酸结合,使该化合物在胆汁中更易溶解。这可防止碘番酸在胆囊中沉淀,并避免从肠道再吸收。(6) 胆盐有助于碘番酸的胆汁排泄。因此,与碘番酸一起服用高脂餐不仅会增加碘番酸的肠道吸收速率,还会增加胆汁排泄速率。(7) 口服和静脉造影剂的胆汁排泄速率似乎都受到肝脏转运最大值的限制。超过一定剂量后,造影剂用量增加并不会使造影剂更快地排泄到胆汁中。快速静脉注射造影剂会导致血浆浓度升高和尿排泄增加,而不会增加胆汁排泄。在临床实践中似乎并不适用。(8) 用于静脉胆管造影的造影剂在胆汁中的浓度取决于其胆汁排泄速率、造影剂的利胆作用以及决定基础胆汁流量速率的因素。水与这些造影剂胆汁排泄的固定耦合对造影剂在胆汁中的浓度造成了固有限制。似乎在静脉胆管造影前让患者禁食可以提高静脉造影剂在胆汁中的浓度。这会减少胆盐的肠肝循环以及胆盐依赖性胆汁流量速率。(9) 在有足够胆汁排泄的情况下,服用碘番酸后胆囊未能显影可能是由于胆囊管阻塞、发炎的胆囊黏膜无法再吸收水分,或者患病的胆囊黏膜对造影剂进行了再吸收。(10) 碘番酸的最大浓度在摄入后14 - 19小时出现。此时应进行胆囊造影。使用胆影葡胺时,峰值浓度在10小时出现,因此使用胆影葡胺时可以更早进行造影。